Cardiovascular risk in people with primary biliary cholangitis: a literature review
Abstract
Primary Biliary Cholangitis (PBC ) is a multifactorial autoimmune disease influenced by genetic factors and environmental triggers such as geographic location, smoking, microorganisms, xenobiotics. This study aims to elucidate the risk factors associated with PBC and its impact on cardiovascular risk. A comprehensive literature search was conducted across databases including original research, prospective and retrospective cohort studies, case-control studies, systematic reviews, and meta-analyses, utilizing relevant keywords. Evidence suggests a correlation between PBC related alterations in the lipid profile, increased oxidative stress, and endothelial dysfunction; however, studies attempting to determine the effect of hypercholesterolemia on the increase in Cardio Vascular Risk (CVR ) in patients with PBC have yield contradictory results. Hepatic steatosis is associated with an elevated risk of Cardiovascular Disease (CV D) and is common in chronic liver diseases such as chronic hepatitis B and C, as well as non-alcoholic fatty liver disease. PBC can manifest extrahepatically, with
pulmonary conditions such as interstitial lung disease and pulmonary hypertension being among the most prevalent. This article explores the relationship between PBC and its primary risk factors, as well as the development of both hepatic and extrahepatic conditions contributing cardiovascular risk.
Downloads
References
Suraweera D, Fanous C, Jimenez M, Tong MJ, Saab S. Risk of cardiovascular events in patients with primary biliary cholangitis-systematic review. J Clin Transl Hepatol. 2018;6(2):119–26.
Gulamhusein AF, Hirschfield GM. Primary biliary cholangitis: pathogenesis and therapeutic opportunities. Nat Rev Gastroenterol Hepatol [Internet]. 2020;17(2):93–110. Available from: http://dx.doi.org/10.1038/s41575-019-0226-7
Reshetnyak VI, Maev I V. Features of Lipid Metabolism Disorders in Primary Biliary Cholangitis. Biomedicines. [Internet]. 2022;10(12). Disponible en: https://doi.org/10.3390%2Fbiomedicines10123046
Loria P, Marchesini G, Nascimbeni F, Ballestri S, Maurantonio M, Carubbi F, et al. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Atherosclerosis [Internet]. 2014;232(1):99–109. Available from: http://dx.doi.org/10.1016/j.atherosclerosis.2013.10.030
Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: A systematic review. Atherosclerosis. 2007;194(2):293–9. Disponible en: https://doi.org/10.1016/j.atherosclerosis.2006.11.036
Yao S, Iwashita A, Yagi S, Watanabe H, Nishio T, Koyama Y, et al. Acute coronary syndrome after liver transplantation in a young primary biliary cholangitis recipient with dyslipidemia: a case report. Surg Case Reports [Internet]. 2022;8(1):1–7. Available from: https://doi.org/10.1186/s40792-022-01470-1
Park B, Islam S, Vemulapalli RC, Shreve ME. Primary biliary cholangitis presenting as acute ischemic stroke: A rare association. Clin Case Reports. [Internet]. 2020;8(2):274–7. Disponible en: https://doi.org/10.1002%2Fccr3.2590
Floreani A, Cazzagon N, Franceschet I, Canesso F, Salmaso L and Baldo V. Metabolic Syndrome Associated With Primary Biliary Cirrhosis. J Clin Gastroenterol. [Internet]. 2015;49(1):57–60.Disponible en: https://doi.org/10.1097/mcg.0000000000000029
Cazzagon N, Dal Lin C, Famoso G, Montisci R, Franceschet I, Floreani A, et al. Coronary flow reserve in patients with primary biliary cholangitis. Dig Liver Dis [Internet]. 2019;51(4):542–8. Disponible en:https://doi.org/10.1016/j.dld.2018.10.016
Bian S, Chen H, Wang L, Fei Y, Yang Y, Peng L, et al. Cardiac involvement in patients with primary biliary cholangitis: A 14-year longitudinal surveybased study. PLoS One. [Internet]. 2018;13(3):1–9. Disponible en: https://doi.org/10.1371/journal.pone.0194397
Maeda MH, Tsuji S, Shimizu J. Inflammator myopathies associated with anti-mitochondrial antibodies. Brain. [Internet]. 2012;135(6):1767–77. Disponible en: https://doi.org/10.1093/brain/aws106
Kenneth R. Feingold M. Endotext [Internet]. Feingold KR, Anawalt B, Blackman MR, et al. E, editor. South Dartmouth (MA): MDText.com, Inc.; 2000-.; 2021. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK305896/
Chen L, Chen XW, Huang X, Song BL, Wang Y, Wang Y. Regulation of glucose and lipid metabolism in health and disease. Sci China Life Sci. [Internet].62(11):1420–58. Disponible en: https://doi.org/10.1007/s11427-019-1563-3
Jebari-Benslaiman S, Galicia-García U, Larrea-Sebal A, Olaetxea JR, Alloza I, Vandenbroeck K, et al.Pathophysiology of Atherosclerosis. Int J Mol Sci.[Internet]. 2022;23(6):1–38. Disponible en: https://doi.org/10.3390%2Fijms23063346
Sanuja Fernando, Bursill C, Nicholls S and Psaltis P. Pathophysiology of Atherosclerosis. Third Edit. Fitridge R, editor. Springer; 2020. 19–46 p. Disponible en: http://dx.doi.org/10.1007/978-3-030-43683-4_2
Loaeza-del Castillo AM, Gaytán-Santillán A, López-Tello A, Merit MVA, Milke-García M del P,Flores-Rodríguez J, et al. Patterns of serum lipids derangements and cardiovascular risk assessment in patients with primary biliary cholangitis. Ann Hepatol [Internet]. 2019;18(6):879–82. Disponible en:https://doi.org/10.1016/j.aohep.2019.07.006
Wah-Suarez MI, Danford CJ, Patwardhan VR, Jiang ZG, Bonder A. Hyperlipidaemia in primary biliary cholangitis: Treatment, safety and efficacy. Frontline Gastroenterol. [Internet] 2019;10(4):401–8. Disponible en: https://doi.org/10.1136/flgastro-2018-101124
Zhang Y, Hu X, Chang J, Chen J, Han X, Zhang T, et al. The liver steatosis severity and lipid characteristics in primary biliary cholangitis. BMC Gastroenterol [Internet]. 2021;21(1):1–8. Disponible en: https://doi.org/10.1186/s12876-021-01974-4
Allocca M, Crosignani A, Gritti A, Ghilardi G, Gobatti D, Caruso D, et al. Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. Gut. [Internet]. 2006;55(12):1795–800. Disponible en: https://doi.org/10.1136%2Fgut.2005.079814
Longo M, Crosignani A, Battezzati PM, Squarcia Giussani C, Invernizzi P, Zuin M, et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut. [Internet]. 2002;51(2):265–9. Disponible en: https://doi.org/10.1136/gut.51.2.265
Crippin JS, Lindor KD, Jorgensen R, Kottke BA, Harrison JM, Murtaugh PA, et al. Hypercholesterolemia and atherosclerosis in primary
biliary cirrhosis: What is the risk? Hepatology. [Internet]. 1992;15(5):858–62. Disponible en: https://doi.org/10.1002/hep.1840150518
Van Dam GM, Gips CH. Primary biliary cirrhosis in The Netherlands. An analysis of associated diseases, cardiovascular risk, and malignancies on the basis of mortality figures. Scand J Gastroenterol. [Internet]. 1997;32(1):77–83. Disponible en: https://doi.org/10.3109/00365529709025067
Solaymani-Dodaran M, Aithal GP, Card T, West J. Risk of cardiovascular and cerebrovascular events in primary biliary cirrhosis: A populationbased cohort study. Am J Gastroenterol. [Internet]. 2008;103(11):2784–8. Disponible en: https://doi.org/10.1111/j.1572-0241.2008.02092.x
Doycheva I, Chen C, Pan JJ, Levy C. Asymptomatic primary biliary cirrhosis is not associated with increased frequency of cardiovascular disease. World J Hepatol. [Internet]. 2011;3(4):93–8. Disponible en: https://doi.org/10.4254%2Fwjh.v3.i4.93
Zöller B, Li X, Sundquist J, Sundquist K. Risk of subsequent coronary heart disease in patients hospitalized for immune-mediated diseases: A nationwide follow-up study from Sweden. PLoS One. [Internet]. 2012;7(3):1–8. Disponible en: https://doi.org/10.1371/journal.pone.0033442
Wang C, Zhao P, Liu W. Brief Communication Risk of incident coronary artery disease in patients with primary biliary cirrhosis. Int J Clin Exp Med [Internet]. 2014;7(9):2921–4. Available from: www.ijcem.com
Gîrleanu I, Trifan A, Huiban L, Muzîca C, Petrea OC, Sîngeap AM, et al. Ischemic Heart Disease and Liver Cirrhosis: Adding Insult to Injury. Life. [Internet]. 2022;12(7). Disponible en: https://doi.org/10.3390%2Flife12071036
Cardinale V, Lleo A. Coronary flow reserve is an innovative tool for the early detection of cardiovascular dysfunction in primary biliary cholangitis patients. Dig Liver Dis [Internet]. 2019;51(4):549–50. Available from: https://doi.org/10.1016/j.dld.2018.11.017
Jones DEJ, Hollingsworth K, Fattakhova G, MacGowan G, Taylor R, Blamire A, et al. Impaired cardiovascular function in primary biliary cirrhosis. Am J Physiol - Gastrointest Liver Physiol. [Internet]. 2010;298(5):764–73. Disponible en: https://doi.org/10.1152%2Fajpgi.00501.2009
Copyright (c) 2024 Revista Med
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
